Kidswell Bio Corporation · TSE:4584
Kidswell Bio — Q3 FY2023 Earnings Presentation
21 slides from Kidswell Bio's earnings presentation, Feb 7, 2024
Slide 1: Financial Results for 3Q FY 2023
Security Code: 4584 Financial Results for 3Q FY 2023 (Fiscal Year Ending March 31, 2024) February 7, 2024 Biotech Striving for Value Creation －For a Comprehensive Healthcare System for Children, Families, and Society － Kidswell Bio Corporation
Slide 2: Agenda
Agenda ◆ Financial Highlights in the 3Q FY2023 ◆ Strategies for Maximizing Corporate Value ◆ Biosimilars Business Updates ◆ Cell Therapy Business Updates - Establishment plan of S-Quatre Corporation - ◆ IR Strategies Copyright © 2024 Kidswell Bio Corporation All Rights Reserved. 2
Slide 3: Financial Highlights in the 3Q FY2023
Financial Highlights in the 3Q FY2023 3
Slide 4: Financial Results in 3Q FY 2023 (PL): Income Statement
Financial Results in 3Q FY 2023 (PL): Income Statement Unit：thousands yen FY2023 ending March 31, 2024 Subject Results for 3Q FY2022 Year-on- Progress Results for 3Q Forecast year ratio rate Gross sales 1,726,862 1,566,742 91% 3,500,000 45% Cost of goods sold 654,042 703,808 108% Gross profit 1,072,
Slide 5: Financial Results in 3Q FY 2023: Balance Sheet
Financial Results in 3Q FY 2023: Balance Sheet Unit：thousands yen Subject 4Q FY2022 3Q FY2023 Current assets 3,697,155 5,036,812 （Cash and cash equivalents） 1,067,162 2,186,682 （Trade receivables） 1,088,766 481,855 （Products） 213,007 187,960 （In-process inventory） 422,308 1,149,405 （Advance payments
Slide 6: Strategies for Maximizing Corporate Value
Strategies for Maximizing Corporate Value 6
Slide 7: KWB's management issues
KWB’s management issues ①Concentration of ② Optimization of financing ③ Visualization of business management resource methods value Maximizing corporate value, realizing stock price recovery and improvement Copyright © 2024 Kidswell Bio Corporation All Rights Reserved. 7
Slide 8: Concentration of management resource
① Concentration of management resource Business progress by the end of 2023 New Biologics Business Biosimilars Business Cell Therapy Business • Launched four BS products through collaborative development with partner • Started clinical development with the • Patent applications have been companies.
Slide 9: Optimization of financing methods; Visualization of business value
② Optimization of financing methods ③ Visualization of business value • By making the biosimilars business and the cell therapy business separate companies, KWB expects to ➢ carry out financing measures according to the characteristics of each business, ➢ improve the "visualization of business value
Slide 10: Biosimilars Business Updates
Biosimilars Business Updates 10
Slide 11: Topics
Topics Accelerate further growth while focusing on maximizing profits from launched products For growth of launched products after FY2024 ◆ Strategies for increased demand ✓ For responding to the steady increase in demand, KWB will continue to expand the manufacturing capacity of CMOs (partially com
Slide 12: Cell Therapy Business Updates
Cell Therapy Business Updates - Establishment plan of S-Quatre Corporation - 12
Slide 13: Outline of establishment plan of the new company
Outline of establishment plan of the new company • The cell therapy business using stem cells from human exfoliated deciduous teeth (SHED), which R&D activity is driven as a future growth business, will be separated from KWB and succeeded to the new company, S-Quatre Corporation. • The new company w
Slide 14: S-Quatre: SHED business plan
S-Quatre: SHED business plan For maximizing the value of S-Quatre®, S-Quatre will flexibly promote collaboration with partner companies, secure external funds and aim to accelerate the development of SHED. Major R&D activities Expanding the use of SHED in a variety of modalities First generation SHE
Slide 15: SHED Development Status (Cerebral palsy)
SHED Development Status (Cerebral palsy) Autologous SHED • Manufacture of SHED from Establishment of Approved by Committee for the patient's own baby manufacturing and Regenerative Clinical research (Nagoya Univ.) administration methods teeth Medicine • Administered to the patient Under enrollment o
Slide 16: IR Strategies
IR Strategies 16
Slide 17: IR Seminars
IR seminars Basic IR Policy：Increase opportunities for dialogue with the stock market and investors ＜Annual IR Schedule＞ 2Q FY2023 3Q FY2023 4Q FY2023 1Q FY2024 Jan. Jul. Aug. Sep. Oct. Nov. Dec. Feb. Mar. Apr. May Jun. 2024 Announcement of Financial Announcement of Announcement of Share- Results An
Slide 18: KIDS WELL, ALL WELL
KIDS WELL, ALL WELL All for Kids, Kids for All
Slide 19: Cautionary Statement
Cautionary Statement This information material is provided for understanding Kidswell Bio Corporation (“KWB”), not for soliciting investment in KWB shares. Information provided in this material may contain so-called “forward-looking statements.” These statements are based on current expectations, fo
Slide 20: Appendix
Appendix 20
Slide 21: Biography
Biography Yasuyuki Mitani, PhD CEO, S-Quatre Corporation (scheduled on Apr 1, 2024) 1996 BS, Pharmaceutical Science, Kyoto University. Obtained a license for pharmacist. MS, Biophysics, Graduate School of Pharmaceutical Sciences, Kyoto University. 1998 Joined Astellas Pharma (f/k/a Fujisawa Pharmace